Reviewed listing: NASDAQ:PTCT · Analysis dated Oct 22, 2026
It has not been confirmed whether the basis of this analysis still holds today. Read it as a dated earlier assessment; it does not establish a current buying opportunity.
How does the company make money?
PTC develops and sells medicines for rare diseases. Its main new growth product is Sephience for the metabolic disease phenylketonuria; older products are coming under pressure.
What supports the business?
Product revenue rose by around 71% in the first half. Sephience already generated revenue of 151.3 million USD in the second quarter and broadens the revenue base.
What could improve?
Successful further market expansion could increase earnings. The acquired gene therapy ST-920 offers additional opportunities, but it is not yet approved and incurs additional costs.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
62.62 USD is above the model midpoint of 48.92 USD. My own cautious price ceiling of 44.00 USD leaves room for setbacks in growth, regulatory approval, and costs.
What is the main risk?
Some reported revenue brings PTC no new money: the Evrysdi royalty payments have been fully sold. New therapies, older products nearing the end of their life cycles, and high development costs make future earnings power uncertain.
What is the overall assessment?
Watch: Sephience is growing strongly and improving PTC's product base. But the share price requires more sustainable cash surplus than the figures to date, without one-time revenue, substantiate.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign in